Studies in the neoadjuvant and adjuvant settings of pancreatic cancer have brought excitement to this treatment paradigm. According to Afsaneh Barzi, MD, some of the most eagerly anticipated data in the field are from a combination study of adjuvant gemcitabine and nab-paclitaxel (Abraxane).
The randomized phase III APACT trial is exploring adjuvant treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Read more . . .